METHODS AND COMPOSITIONS INVOLVING MIRNA AND MIRNA INHIBITOR MOLECULES
3 Assignments
0 Petitions
Accused Products
Abstract
The present invention concerns methods and compositions for introducing miRNA activity or function into cells using synthetic nucleic acid molecules. Moreover, the present invention concerns methods and compositions for identifying miRNAs with specific cellular functions that are relevant to therapeutic, diagnostic, and prognostic applications wherein synthetic miRNAs and/or miRNA inhibitors are used in library screening assays.
-
Citations
106 Claims
-
1-66. -66. (canceled)
-
67. A method for reducing or inhibiting cell proliferation in a cell comprising introducing into the cell an effective amount of at least one
i) miRNA inhibitor molecule that is between 17 and 25 nucleotides in length and comprises a 5′ - to 3′
sequence that is at least 90% omplementary to the 5′
to 3′
sequence of a mature miRNA selected from the group consisting of;
mir-31, mir-92, mir-99a, mir-100, mir-125a, mir-129, mir-130a, mir-150, mir-187, miR-190, miR-191, miR-193, miR 204, mir-210, mir-211, mir-212, mir-213, mir-215, mir-216, mir-217, miR 218, mir-224, mir-292, mir-294, mir-320, mir-324, mir-325, mir-326, mir-330, mir-331, mir-338, mir-341, mir-369, and mir-370;
orii) synthetic miRNA molecule of between 17 and 125 residues in length comprising an miRNA region whose sequence from 5′
to 3′
is identical to a mature miRNA sequence, and a complementary region whose sequence from 5′
to 3′
is between 60% and 100% complementary to the mature miRNA sequence, wherein the mature miRNA sequence is selected from the group consisting of;
miR-15a, miR-16, miR 21, miR 24, miR-96, miR-101, miR-105, miR-124, miR-126, miR-142, miR-147, miR-192, miR-194, miR-206, miR-215, or miR-346. - View Dependent Claims (68)
- to 3′
-
69-70. -70. (canceled)
-
71. A method for reducing cell viability comprising introducing into one or more cells an effective amount of at least one
i) miRNA inhibitor molecule that is between 17 and 25 nucleotides in length and comprises a 5′ - to 3′
sequence that is at least 90% complementary to the 5′
to 3′
sequence of a mature miRNA selected from the group consisting of;
miR-107, miR-133, miR-137, miR-152, miR-155, miR-181 a, miR-191, miR-203, and miR-215;
orii) synthetic miRNA molecule of between 17 and 125 residues in length comprising an miRNA region whose sequence from 5′
to 3′
is identical to a mature miRNA sequence, and a complementary region whose sequence from 5′
to 3′
is between 60% and 100% complementary to the miRNA sequence selected from the group consisting of;
mir-1, mir-7, miR-10b, miR-17-3p, miR-19a, mir-23, mir-24, mir-27a, miR-29a, miR-30a-3p, mir-31, mir-32, miR-34a, miR-101, miR-107, miR-108, miR-122, mir-124, miR-133a, miR-134, miR-135, miR-139, mir-140, miR-141, miR-145, mir-150, mir-192, mir-193, mir-195, mir-206, mir-208, mir-210, mir-210, mir-292-3p, mir-293, mir-297, mir-299, mir-329, mir-337, mir-337, mir-345, mir-346, and mir-409. - View Dependent Claims (72)
- to 3′
-
73-74. -74. (canceled)
-
75. A method for inducing apoptosis in a cell comprising introducing into the cell an effective amount of at least one
i) miRNA inhibitor molecule that is between 17 and 25 nucleotides in length and comprises a 5′ - to 3′
sequence that is at least 90% complementary to the 5′
to 3′
sequence of a mature miRNA selected from the group consisting of;
miR-31 and miR-214;
orii) synthetic miRNA molecule of between 17 and 125 residues in length comprising an miRNA region whose sequence from 5′
to 3′
is identical to a mature miRNA sequence, and a complementary region whose sequence from 5′
to 3′
is between 60% and 100% complementary to the miRNA sequence selected from the group consisting of;
mir-1, mir-1d, mir-7, mir-10a, miR-10b, miR-17-3p, miR-19a, miR-28, miR-28, miR-28, miR-29a, miR-32, miR-34a, miR-122, mir-148, mir-149, mir-154, mir-184, mir-186, mir-188, mir-192, mir-195, mir-196, mir-199a, mir-204, mir-208,mir-210, mir-21 1, mir-212, mir-214, mir-215, mir-216, mir-217, mir-218, mir-293, mir-296, mir-299, mir-321, mir-328, and mir-344. - View Dependent Claims (76)
- to 3′
-
77-101. -101. (canceled)
-
102. A method comprising providing to cells:
-
a) at least one miRNA inhibitor that is between 17 and 25 nucleotides in length and that comprises a 5′
to 3′
sequence that is at least 90% complementary to the 5′
to 3′
sequence of a mature miRNA orb) at least one synthetic RNA molecule of between 17 and 125 residues in length comprising i) an miRNA region whose sequence from 5′
to 3′
is identical to a mature miRNA sequence, and ii) a complementary region whose sequence from 5′
to 3′
is between 60% and 100% complementary to the mature miRNA sequence,wherein the mature miRNA is selected from the group consisting of;
miR-1, miR-1-d, miR-1-2, miR-9, miR-10a, miR-10b, miR-15a, miR-16, miR-17, miR-17-3p, miR-18, miR-19a, miR-20, miR-21, miR-22, miR-23, miR-23a, miR-23b, miR-24, miR-25, miR-26a, miR-27a, miR-28, miR-29a, miR-29b, miR-30a-3p, miR-30a, miR-30e-5p, miR-31, miR-32, miR-34a, miR-92, miR-93, miR-95, miR-96, miR-98, miR-99a, miR-100, miR-101, miR-105, miR-106, miR-107, miR-108, miR-122, miR-124, miR-125, miR-125b, miR-126, miR-127, miR-128, miR-129, miR-130, miR-130a, miR-133, miR-133a, miR-133a-2, miR-133b, miR-134, miR-135, miR-137, miR-138, miR-139, miR-140, miR-141, miR-142, miR-143, miR-145, miR-147, miR-148, miR-149, miR-150, miR-152, miR-153, miR-154, miR-155, miR-181, miR-182, miR-183, miR-184, miR-186, miR-187, miR-188, miR-190, miR-191, miR-192, miR-193, miR-194, miR-195, miR-196, miR-197, miR-198, miR-199, miR-199a-1, miR-200b, miR-201, miR-203, miR-204, miR-206, miR-207, miR-208, miR-210, miR-211, miR-212, miR-213, miR-214, miR-215, miR-216, miR-217, miR-218, miR-222, miR-223, miR-224, miR-291-3p, miR-292, miR-292-3p, miR-293, miR-294, miR-295, miR-296, miR-297, miR-298, miR-299, miR-320, miR-321, miR-322, miR-324, miR-325, miR-326, miR-328, miR-329, miR-330, miR-331, miR-333, miR-335, miR-337, miR-338, miR-340, miR-341, miR-342, miR-344, miR-345, miR-346, miR-350, miR-367, miR-368, miR-369, miR-370, miR-371, miR-373, miR-380-3p, miR-409, miR-410, or miR-412. - View Dependent Claims (103, 104, 105, 106)
-
Specification